Pharmac, New Zealand’s only agency under government which purchases drugs, has announced plans to invest money in another drug to help New Zealanders who are narcoleptic. The funding, to be granted to drug manufacturer Modafnil, will stretch for five years and will cost $50,000 short of a million dollars.
The drug will become available to New Zealanders beginning on the first day of May and is expected to help people who suffer from extreme fatigue during daytime up to the point of falling asleep all of a sudden. The usual treatment for narcolepsy is taking a stimulant drug. According to Pharmac Medical Director Peter Moodie, around two hundred New Zealanders have already benefited from the drug known as Methylphenidate, otherwise known as Dexamphetamine.
Moodie explains that “clinical trial results show that, for some people, Modafanil can be a more effective-treatment than other stimulant drugs, so this is a useful addition to funded treatments.”